Search Bar & Filters
Found 22 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of different doses of a new medicine called NNC0519-0130 in people living with chronic kidney disease, some of whom have type 2 diabetes and are overweight or obese. This Phase 2 study also compares NNC0519-0130 to semaglutide, an already prescribed medicine, and a placebo to see how they may improve kidney function. Participants will be randomly assigned to receive once-weekly subcutaneous injections of NNC0519-0130 with a fixed dose escalation until reaching a maintenance dose, semaglutide with a similar dosing schedule, or a placebo matching NNC0519-0130. The treatment period lasts up to 43 weeks with several dosing schemes and groups. During the study, participants will have their kidney function monitored through urine albumin-to-creatinine ratio changes at weeks 12, 24, and 36. Other assessments include estimated glomerular filtration rate, body weight changes, waist circumference, blood pressure, and glycated hemoglobin levels. Safety will be evaluated by tracking adverse events throughout the trial duration. Participants will be regularly assessed to understand the medicines effects and safety.
Actively Recruiting
Researchers are evaluating denecimig Mim8 for adults diagnosed with acquired haemophilia A, a rare bleeding disorder. This Phase 3 open-label study aims to assess the safety and effectiveness of denecimig in reducing bleeding episodes in this population. The study is sponsored by Novo Nordisk AS and will follow participants for up to about one year and five months. Participants will receive subcutaneous injections of denecimig during the study. The treatment period includes a main part lasting 12 weeks followed by an extension phase up to 52 weeks. Denecimig plasma levels and the occurrence of antidrug antibodies will be monitored throughout the treatment. The study also tracks bleeding events and the use of other bleeding management therapies. During the study, participants will be closely monitored for treated and clinically relevant bleeding episodes, infections, and immune responses. The primary outcome is the number of treated bleeds during the first 12 weeks of treatment. Secondary outcomes include bleeding frequency, treatment days with bypassing agents or factor VIII products, and denecimig plasma concentration over one year. Participants are expected to follow study procedures and seek medical attention as needed during the approximately 73-week study period.
Actively Recruiting
This research aims to evaluate the safety of the medicine eptacog alfa in women in India who experience severe heavy bleeding after giving birth, known as severe postpartum haemorrhage PPH. The study focuses on women aged 18 years or older who have given birth after 27 weeks of pregnancy and have PPH that does not respond to standard uterotonic treatments. The goal is to gather more knowledge about how safe eptacog alfa is when used for this purpose. Participants will receive a single intravenous bolus injection of eptacog alfa NovoSeven to help stop the bleeding. If the first dose does not stop the bleeding, an additional dose may be given. This study is a Phase IV interventional trial conducted with a single treatment group and will last about 30 to 35 days for each participant. During the study, participants will be monitored for any thromboembolic events from the start of treatment through 30 days after. Researchers will also track serious adverse events, allergic reactions, and any medication errors at baseline and throughout the study period. The study involves careful observation and safety monitoring to understand the effects of eptacog alfa in these women.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate KarXT in adults with Bipolar-I disorder experiencing acute manic or mixed episodes. The study focuses on assessing how well KarXT works compared to a placebo during a three-week inpatient treatment period. Participants must be hospitalized due to their acute symptoms, and the study includes a total duration of up to seven weeks covering screening, treatment, and safety follow-up. Participants are randomly assigned to receive either KarXT or a placebo with flexible dosing during the inpatient phase. The main goal is to observe changes in manic symptoms using the Young Mania Rating Scale over three weeks. The study monitors safety and efficacy through standardized psychiatric assessments and follows participants closely during the inpatient stay. During the trial, participants will undergo regular evaluations including psychiatric ratings and clinical global impressions to track symptom changes and treatment response. The study includes initial screening, a three-week double-blind treatment period while hospitalized, and a safety follow-up period to monitor participants health. The total participation time does not exceed seven weeks.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.
Actively Recruiting
Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.
Actively Recruiting
Researchers are identifying and characterizing patients with Type 2 Diabetes Mellitus T2DM to support participation in current or future clinical studies focused on this condition. The study aims to observe trends in key medications used alongside diabetes treatments across various geographical areas, helping to better understand patient profiles and treatment patterns. Participants with T2DM who are inadequately managed by lifestyle changes alone or stable on glucose-lowering medications for at least 45 days will be observed. The study involves a single visit where assessments include collecting about 2 mL of blood and recording medical history, medication use, and HbA1c levels. This observational study does not administer treatments but gathers important health information. During the study visit, participants will provide demographic details, medical and surgical history, current medications, and blood samples to measure HbA1c levels. Researchers will also note referrals to ongoing or future T2DM studies. Participation requires signed consent and willingness to follow study procedures. The study concludes after the single visit, with no further follow-up required.
1-10 of 22
1